#China #Shanghai #Innovation #biotechnology #Henlius

Henlius Reports Flourishing Growth in First Half of 2025

Henlius (2696.HK), a prominent player in the biopharmaceutical sector, has disclosed its interim results for 2025, highlighting an impressive revenue of approximately RMB 2.8195 billion in the first half of the year. This marks a year-on-year increase of 2.7%. Furthermore, the company has reported a gross profit of RMB 2.1992 billion, which reflects a substantial increase of 10.5% compared to the same period last year. Notably, the net profit stood at RMB 390.1 million, underscoring the company's financial stability amidst its global expansion efforts.

One of the standout metrics from the report is the remarkable surge in profits derived from overseas products, which skyrocketed by over 200%. Henlius has experienced a significant influx in cash from business development agreements, exceeding RMB 1 billion, a staggering increase of 280% year-on-year. The company's focus on international markets has been pivotal, as evidenced by the continuous rise in the volume of sales for commercialized products. Given this positive trajectory, Henlius anticipates notable growth in its overseas revenue and profits throughout the entirety of 2025, with expectations of sustaining this momentum into 2026.

A core component of Henlius's ongoing success is its robust commitment to innovation and globalization. The company actively pursues initiatives aimed at enhancing its end-to-end ecosystem, placing a strong emphasis on sustainable research and development growth. In the first half of 2025, Henlius dedicated RMB 995.4 million specifically to R&D, marking a 21.3% increase in expenditures allocated for preclinical development of differentiated innovative molecules and the establishment of core innovative platforms.

As of the latest data, Henlius has successfully launched six products in China, with four having obtained approval for marketing in international markets. To date, these innovations have benefitted over 850,000 patients across approximately 60 countries within Asia, Europe, Latin America, North America, and Oceania. The company is also expanding its innovation pipeline to target critical disease areas, particularly oncology and autoimmune diseases, establishing a differentiated portfolio that includes potential best-in-class and first-in-class candidates.

Dr. Jason Zhu, the Executive Director and Chief Executive Officer of Henlius, emphasized the significance of 2025, stating, "This is a pivotal year for Henlius as we transition into Globalization 2.0 and accelerate our innovation pace. Our efforts are centered around enhancing our end-to-end ecosystem while driving overseas revenue growth to achieve global value at scale. Our innovative products have reached significant milestones, and the next generation of high-potential molecules is in progress. Moving forward, Henlius is dedicated to maintaining a patient-centric approach, bringing forth superior innovative treatment solutions."

During the first six months of 2025, Henlius’s global growth engine was in full effect, with global product revenue surpassing RMB 2.5568 billion, a 3.1% increase from the previous year. The company’s core product, serplulimab (marketed as HANSIZHUANG in China and Hetronifly® in Europe), which is the first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC), generated global sales of RMB 597.7 million. The product has gained traction in several international markets, receiving approvals in multiple countries such as the UK, India, and Malaysia for treating extensive-stage small cell lung cancer.

Additionally, Henlius's breast cancer product, HANQUYOU (trastuzumab, known as HERCESSI™ in the U.S.), demonstrated significant revenue generation of RMB 1.4442 billion in the first half of 2025. Recently, it received new approvals, increasing its cumulative endorsements to over 50 countries and regions. Henlius actively pursues research to develop a comprehensive innovative product portfolio focused on breast cancer therapies, combining its existing products with novel therapeutic strategies to reduce recurrence risks among early-stage patients.

In a broader sense, Henlius is strengthening its international collaboration, entering into various agreements to license the development and commercialization of its biosimilars and innovative biologics across diverse emerging markets. Furthermore, the company is enhancing its integrated biopharmaceutical platform by focusing on R&D, clinical trials, manufacturing, and regulatory affairs, successfully submitting over 800 drug registrations to date.

Overall, Henlius is poised for sustained growth as it capitalizes on its innovative pipeline and international market strategies. With its ongoing dedication to breaking through healthcare boundaries while addressing unmet clinical needs, the company remains committed to improving the lives of patients worldwide by providing high-quality and affordable biologic medicines.